Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Co-founded in 2023 Volnay Therapeutics. We are slowly coming out of stealth mode.
Between 2017-2022 served as a member of Takeda’s R&D leadership team. Leading Takeda R&D’s CMC efforts in developing and integrating strategies and knowledge across our diverse modality and technology ecosystem.
Responsible for Takeda R&D’s CMC activities and for the development of medical devices in the R&D and commercial space, driven by Takeda’s Pharmaceutical Sciences organization.
Responsible for the process development and translational efforts to develop and advance cell therapies, driven by Takeda’s Cell Therapy Translational Engine.
Leading a global organization with researchers in the greater Boston area (US), San Diego (US), Vienna (Austria), and in the greater Tokyo area (Japan).
The Pharmaceutical sciences teams develop medical devices, (bio)analytical methods, drug-substance and drug product processes for diverse modalities, reaching from synthetic molecules to nucleic acids, enzymes, fusion proteins, gene-therapies and antibodies to the microbiome. We heavily invest in the development and introduction of digital tools.
Until mid 2021 lead the creation and implementation of Takeda’s Cell Therapy Translational Engine. An organization operating as an integrated team that consists of automation and data-specialists, translational and process development experts, bioanalytical scientists and a CMC-regulatory team. The Cell Therapy Translational Engine (CTTE) has the goal to rapidly develop differentiated therapies with a strategic focus on “off-the-shelf” allogeneic cell-therapies, iPSC platforms and ex-vivo cell therapies. The engine successfully collaborates on a global level with researchers external and internal to Takeda.
The PharmSci and CTTE teams embrace digital technologies and support all development stages – from pre-clinical through phase 3 and the transfer to commercial manufacturing.
We manufacture clinical trial material and we are proud collaborators and value-adding enablers of our partners, external as well as internal.
